Near clinical testing translates into better informed decisions

10 May 2024

Testing models or patients…?

A growing gap has emerged between research models in the lab and patients that require their new treatments. In a time of escalating costs, high attrition rates, limited resources and extended timelines we need to invest in highly translational research.

The advantage of using patient's ex vivo micro tumors:

✅ Fast -> Actionable results in 2 weeks

✅ Relevant -> Includes native tumor micro environment (TME)

✅ Highly translational -> Represent intratumor heterogeneity

✅ Proven predictive -> Ex vivo responses correlate with clinical outcome measures

Accelerate and increase the succes of drug development by testing patients instead of models!